Last updated on April 2019

Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer


Brief description of study

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.

Clinical Study Identifier: NCT02414139

Contact Investigators or Research Sites near you

Start Over

Pacific Shores Medical Group SC

Long Beach, CA United States
  Connect »

VA Comprehensive Cancer Center

West Haven, CT United States
  Connect »

Decatur Memorial Hospital

Decatur, IL United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Henry Ford Hospital SC

Detroit, MI United States
  Connect »

Minneapolis VA Medical Center

Minneaplois, MI United States
  Connect »

Andrew & Patel Associates,

Camp Hill, PA United States
  Connect »

GHS Cancer Intitute

Greenville, SC United States
  Connect »

Novartis Investigative Site

Sao Jose do Rio Preto, Brazil
  Connect »

Novartis Investigative Site

Marseille cedex 20, France
  Connect »

Novartis Investigative Site

Gyeonggi-do, Korea, Republic of
  Connect »

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Novartis Investigative Site

St Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

St.-Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Tambov, Russian Federation
  Connect »

Novartis Investigative Site

Birmingham, United Kingdom
  Connect »

Novartis Investigative Site

Las Palmas De Gran Canarias, Spain
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

St. Luke's Cancer Institute SC-2

Kansas City, MO United States
  Connect »

Oncology Consultants

Houston, TX United States
  Connect »

Novartis Investigative Site

Saint Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Seongnam-si, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.